The Arabian Gulf region has seen an increasing rise in diabetic foot ulcers (DFUs) with prevalence ranging from 4.7% to 19% in Saudi Arabia (Hu et al, 2014; Mairghani et al, 2017). Current practices for standard of care include wound debridement, wound offloading and dressings. The authors successfully managed diabetic foot ulcers with oxygen free-radical binding technology as an adjuvant therapy for our patients. HemaGel® (VH Pharma), a hydrophilic gel, contains sterically hindered amines that bind with reactive oxygen species (ROS) and thereby accelerates wound healing by showing an anti-inflammatory effect. The three case reports in this article discuss the use of targeted oxygen free radicals to promote wound healing by oxidant/antioxidant disequilibrium methodology in the authors’ patients. With supporting diabetes controlling medications and HemaGel, wound healing was achieved successfully in these patients.